Think Pink Raises $100,000 for Breast Cancer Research
The 2003 Think Pink luncheon, the kick-off to Saks Fifth Avenue's Key to the Cure shopping weekend in Cincinnati, raised approximately $100,000 for cancer research at the UC Cancer Programs/The Barrett Cancer Center. The September 17 event was sold out with 720 guests.
In addition to the money raised during the luncheon, two percent of all sales at Saks Fifth Avenue between September 17-20 will be donated to the Barrett Cancer Center. The final donation total will be announced in January 2004.
Contributions from this year's luncheon and Saks donation will be used for start-up projects to determine why breast cancer rates are so high in the Tristate area. Researchers will work to develop biological insights that will allow for the development of new and innovative treatments. Additional research into early breast cancer detection methods will also be funded.
Tags
Related Stories
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
Ohio nurses weigh in on proposed federal loan rule
December 12, 2025
Spectrum News journalist Javari Burnett spoke with UC Dean Alicia Ribar and UC nursing students Megan Romero and Nevaeh Haskins about proposed new federal student loan rules. Romero and Haskins, both seniors, were filmed in the College of Nursing’s Simulation Lab.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.